HMA Failure is Grim News for AML Patients

Did your older AML patient fail HMA therapy? That’s worse than you think.

Is Hydroxyurea Too Risky to be a First Line Therapy in PV?

Does the standard first-line treatment for PV increase risk of leukemia?

Combination Therapy Delivers Long-Term Remission for CLL Patients

Who benefits most from this current CLL chemoimmunotherapy combo therapy?

FDA Approves TRISENOX Injection for First Line Treatment of Acute Promyelocytic Leukemia

The U.S. Food and Drug Administration has approved the use of the intravenous drug TRISENOX (Teva Pharmaceutical Industries Ltd.) in combination with tretinoin for first line treatment of adult patients who have been newly-diagnosed with low-risk APL.

Adverse Events Caused 81% of Patients to Discontinue TKIs for CML, Study Finds

A new study found that adverse effects were the most common reason for patients with chronic myeloid leukemia to discontinue use of tyrosine kinase inhibitors.

Novartis Approval for Gene Therapy Signals New Cancer Treatment Era

The U.S. Food and Drug Administration gave a green light to Novartis AG's leukemia treatment, marking the first time that a highly anticipated new type of potent gene-modifying immunotherapy has gained approval in the United States.

First Dagabitran Reversal Agent Approved

  • Dabigatran anti-coagulation can now be reversed.
  • FDA approves idarucizumab for reversal of dabigatran anti-coagulation.
  • Normal coagulation is established “in minutes.”
  • Preliminary data show idarucizumab to be safe and effective for reversal of dabigatran anti-coagulation.
  • Both efficacy and safety trials are sponsored by the manufacturer and published in top-tier journals.

© 2024 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use | Editorial Policy | Advertising Policy